ATE333453T1 - Mannich base prodrugs von 3-(pyrrol-2- ylmethylidene)-2-indolinon derivate und deren verwendung als protein kinase inhibitoren - Google Patents

Mannich base prodrugs von 3-(pyrrol-2- ylmethylidene)-2-indolinon derivate und deren verwendung als protein kinase inhibitoren

Info

Publication number: ATE333453T1
Authority: AT; Austria
Prior art keywords: ylmethylidene; pyrrol; protein kinase; kinase inhibitors; mannich base
Prior art date: 2000-05-24

Application number

AT01939357T

Other languages

English (en)

Inventor

Malcolm Wilson Moon

Walter Morozowich

Ping Gao

Peng Cho Tang

Original Assignee

Sugen Inc

Pharmacia & Upjohn Co Llc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-05-24

Filing date

2001-05-24

Publication date

2006-08-15

2001-05-24 Application filed by Sugen Inc, Pharmacia & Upjohn Co Llc filed Critical Sugen Inc

2006-08-15 Application granted granted Critical

2006-08-15 Publication of ATE333453T1 publication Critical patent/ATE333453T1/de

Links

SEZFNTZQMWJIAI-UHFFFAOYSA-N 3-(1H-pyrrol-2-ylmethylidene)-1H-indol-2-one Chemical class O=C1NC2=CC=CC=C2C1=CC1=CC=CN1 SEZFNTZQMWJIAI-UHFFFAOYSA-N 0.000 title 1
229940045988 antineoplastic drug protein kinase inhibitors Drugs 0.000 title 1
229940002612 prodrug Drugs 0.000 title 1
239000000651 prodrug Substances 0.000 title 1
239000003909 protein kinase inhibitor Substances 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
- C07F9/572—Five-membered rings
- C07F9/5728—Five-membered rings condensed with carbocyclic rings or carbocyclic ring systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Animal Behavior & Ethology (AREA)
Bioinformatics & Cheminformatics (AREA)
Diabetes (AREA)
Immunology (AREA)
Biochemistry (AREA)
Biomedical Technology (AREA)
Molecular Biology (AREA)
Neurology (AREA)
Dermatology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Neurosurgery (AREA)
Hematology (AREA)
Physical Education & Sports Medicine (AREA)
Urology & Nephrology (AREA)
Rheumatology (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Obesity (AREA)
Psychiatry (AREA)
Transplantation (AREA)
Endocrinology (AREA)
Emergency Medicine (AREA)
Pulmonology (AREA)
Pain & Pain Management (AREA)
Vascular Medicine (AREA)
Hospice & Palliative Care (AREA)

AT01939357T 2000-05-24 2001-05-24 Mannich base prodrugs von 3-(pyrrol-2- ylmethylidene)-2-indolinon derivate und deren verwendung als protein kinase inhibitoren ATE333453T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US20700000P	2000-05-24	2000-05-24
US22504500P	2000-08-11	2000-08-11

Publications (1)

Publication Number	Publication Date
ATE333453T1 true ATE333453T1 (de)	2006-08-15

Family

ID=26901875

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
AT01937687T ATE312093T1 (de)	2000-05-24	2001-05-24	1-(pyrrolidin-1-ylmethyl)-3-(pyrrol-2- ylmethyliden)-2-indolinon derivate und deren verwendung als protein kinase inhibitoren
AT01939357T ATE333453T1 (de)	2000-05-24	2001-05-24	Mannich base prodrugs von 3-(pyrrol-2- ylmethylidene)-2-indolinon derivate und deren verwendung als protein kinase inhibitoren

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
AT01937687T ATE312093T1 (de)	2000-05-24	2001-05-24	1-(pyrrolidin-1-ylmethyl)-3-(pyrrol-2- ylmethyliden)-2-indolinon derivate und deren verwendung als protein kinase inhibitoren

Country Status (13)

Country	Link
US (8)	US6710067B2 (de)
EP (3)	EP1301507B1 (de)
JP (3)	JP2003534342A (de)
AR (3)	AR042383A1 (de)
AT (2)	ATE312093T1 (de)
AU (3)	AU2001264877A1 (de)
CA (3)	CA2409367A1 (de)
DE (2)	DE60121595T2 (de)
ES (2)	ES2269416T3 (de)
HK (1)	HK1054552B (de)
MY (2)	MY128450A (de)
TW (1)	TWI270545B (de)
WO (3)	WO2001090104A2 (de)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6051593A (en) *	1997-06-20	2000-04-18	Sugen, Inc.	3-(cycloalkanoheteroarylidenyl)-2- indolinone protein tyrosine kinase inhibitors
US20030153015A1 (en) *	2000-01-20	2003-08-14	Genentech, Inc.	Compositions and methods for the treatment of immune related diseases
CZ303705B6 (cs) *	2000-02-15	2013-03-27	Sugen, Inc.	Pyrrolem substituovaná 2-indolinonová sloucenina pro pouzití jako inhibitor proteinkináz a farmaceutická kompozice s jejím obsahem
MY128450A (en) *	2000-05-24	2007-02-28	Upjohn Co	1-(pyrrolidin-1-ylmethyl)-3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives
EP1294688A2 (de) *	2000-06-02	2003-03-26	Sugen, Inc.	Indolinon derivate als protein kinase/phosphatase inhibitoren
AR042586A1 (es) *	2001-02-15	2005-06-29	Sugen Inc	3-(4-amidopirrol-2-ilmetiliden)-2-indolinona como inhibidores de la protein quinasa; sus composiciones farmaceuticas; un metodo para la modulacion de la actividad catalitica de la proteinquinasa; un metodo para tratar o prevenir una afeccion relacionada con la proteinquinasa
US6797725B2 (en) *	2001-04-09	2004-09-28	Sugen, Inc.	Prodrugs of a 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives
AR036042A1 (es)	2001-05-30	2004-08-04	Sugen Inc	Derivados aralquilsufonil-3-(pirrol-2-ilmetiliden)-2-indolinona, sus composiciones farmaceuticas y metodo para la modulacion de la actividad catalitica de una proteina quinasa
WO2003000251A1 (en)	2001-06-21	2003-01-03	Ariad Pharmaceuticals, Inc.	Novel idolinones and uses thereof
US7741335B2 (en)	2001-06-29	2010-06-22	Ab Science	Use of tyrosine kinase inhibitors for treating inflammatory diseases
WO2003004007A2 (en)	2001-06-29	2003-01-16	Ab Science	Use of tyrosine kinase inhibitors for treating inflammatory bowel diseases (ibd)
US20040266797A1 (en) *	2001-06-29	2004-12-30	Alain Moussy	Use of potent,selective and non toxic c-kit inhibitors for treating tumor angiogensis
DE60223063T2 (de)	2001-06-29	2008-07-17	Ab Science	C-kit inhibitoren
ATE388711T1 (de) *	2001-09-20	2008-03-15	Ab Science	C-kithemmer zur behandlung von bakteriellen infektionen
EP1434774A1 (de)	2001-10-10	2004-07-07	Sugen, Inc.	3-(4-substituierte heterocyclyl)-pyrrol-2-ylmethylidene)-2-indolinone derivate als protein-kinase-inhibitoren
EP1453502A4 (de) *	2001-11-21	2007-01-10	Sugen Inc	Pharmazeutische formulierungen mit indolinon-derivaten
US20030187026A1 (en)	2001-12-13	2003-10-02	Qun Li	Kinase inhibitors
US6797825B2 (en)	2001-12-13	2004-09-28	Abbott Laboratories	Protein kinase inhibitors
EP1469810A4 (de) *	2002-01-04	2009-01-14	Univ Rockefeller	Zusammensetzungen und verfahren zur verhütung und behandlung von erkrankungen im zusammenhang mit amyloid-beta peptid
US20050153975A1 (en) *	2002-02-22	2005-07-14	Heinrich Michael C.	Use of 4-(4-Methylpiperazin-1-ylmethyl)-n-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide for treating seminomas
JP2005527203A (ja) *	2002-03-22	2005-09-15	バイエル・フアーマシユーチカルズ・コーポレーシヨン	偽島の調製のための方法
US20050032871A1 (en) *	2002-09-03	2005-02-10	Sugen, Inc.	Sulfonylated pyrrole-2-indolinone derivatives as kinase inhibitors
AR042042A1 (es) *	2002-11-15	2005-06-08	Sugen Inc	Administracion combinada de una indolinona con un agente quimioterapeutico para trastornos de proliferacion celular
EP1581309A4 (de) *	2002-11-15	2009-07-29	Exelixis Inc	Kinase-modulatoren
DE10393799T5 (de) *	2002-11-27	2005-10-13	Allergan, Inc., Irvine	Kinaseinhibitoren für die Behandlung von Erkrankungen
US6747025B1 (en)	2002-11-27	2004-06-08	Allergan, Inc.	Kinase inhibitors for the treatment of disease
US6699863B1 (en)	2002-11-27	2004-03-02	Allergan, Inc.	Kinase inhibitors for the treatment of disease
JP4879492B2 (ja) *	2002-11-27	2012-02-22	アラーガン、インコーポレイテッド	疾患の治療のためのキナーゼ阻害剤
PL376844A1 (pl) *	2002-12-09	2006-01-09	The Board Of Regents Of The University Of Texas System	Sposoby selektywnego hamowania kinazy tyrozynowej 3 z grupy Janus (JAK3)
US7452913B2 (en) *	2003-02-24	2008-11-18	Pharmacia & Upjohn Company	Polymorphs of pyrrole substituted 2-indolinone protein kinase inhibitors
WO2004105763A2 (en) *	2003-05-27	2004-12-09	Haegerkvist Robert Per	Use of tyrosine kinase inhibitor to treat diabetes
ATE506077T1 (de) *	2003-10-16	2011-05-15	Imclone Llc	Fibroblasten-wachstumsfaktor-1-hemmer und behandlungsverfahren dafür
US20050182122A1 (en) *	2003-11-20	2005-08-18	Bello Carlo L.	Method of treating abnormal cell growth using indolinone compounds
US7488817B2 (en) *	2004-02-02	2009-02-10	The Trustees Of The University Of Pennsylvania	Metal complex protein kinase inhibitors
WO2006032164A1 (en) *	2004-09-23	2006-03-30	Beijing Molecule Science And Technology Co., Ltd.	1,3-substitued-2-indolinone derivatives, the preparation, the composition and the use thereof
CN101054379A (zh) *	2006-04-11	2007-10-17	上海恒瑞医药有限公司	吡咯取代的嘧啶酮衍生物、其制备方法及其在医药上的用途
EP2076492A4 (de) *	2006-10-06	2010-12-22	Merck Sharp & Dohme	Nicht-nukleosidische reverse-transkriptase-hemmer
WO2008115499A1 (en) *	2007-03-19	2008-09-25	State Of Oregon Acting By And Through The Oregon State Board Of Higher Education On Behalf Of The University Of Oregon	Mannich base n-oxide drugs
US8642067B2 (en)	2007-04-02	2014-02-04	Allergen, Inc.	Methods and compositions for intraocular administration to treat ocular conditions
US20110009379A1 (en) *	2008-04-01	2011-01-13	Astellas Pharma Inc.	Indolinone compound
US8106039B2 (en) *	2008-04-30	2012-01-31	The Trustees Of The University Of Pennsylvania	Metal complex phosphatidyl-inositol-3-kinase inhibitors
WO2010023474A1 (en) *	2008-08-25	2010-03-04	Generics [Uk] Limited	Novel polymorphs of sunitinib and processes for their preparation
US20120029046A1 (en) *	2008-08-25	2012-02-02	Generics (Uk) Limited	Crystalline form of sunitinib and processes for its preparation
EP2181991A1 (de) *	2008-10-28	2010-05-05	LEK Pharmaceuticals D.D.	Neuartige Sunitinib-Salze
EP2186809A1 (de) *	2008-11-13	2010-05-19	LEK Pharmaceuticals D.D.	Neue kristalline Form von Sunitinib-Malat
WO2010087315A1 (ja) *	2009-01-29	2010-08-05	株式会社林原生物化学研究所	抗アルツハイマー病剤
JPWO2010087313A1 (ja) *	2009-01-29	2012-08-02	株式会社林原生物化学研究所	神経突起伸展促進剤
JP5591720B2 (ja) *	2009-01-29	2014-09-17	株式会社林原	抗神経変性疾患剤
EP2445502B2 (de)	2009-06-25	2022-09-28	Alkermes Pharma Ireland Limited	Heterozyklische verbindungen zur behandlung von neurologischen und psychologischen erkrankungen
CA2937222C (en) *	2009-06-25	2019-06-04	Alkermes Pharma Ireland Limited	Prodrugs of nh-acidic compounds
SG178279A1 (en)	2009-08-05	2012-03-29	Intra Cellular Therapies Inc	Novel regulatory proteins and inhibitors
SG178403A1 (en) *	2009-08-14	2012-03-29	Opko Health Inc	Intravenous formulations of neurokinin-1 antagonists
CA2794153C (en)	2010-03-25	2018-01-02	Glaxosmithkline Llc	Substituted indoline derivatives as perk inhibitors
ES2691671T3 (es)	2010-06-24	2018-11-28	Alkermes Pharma Ireland Limited	Profármacos de compuestos NH-acídicos: derivados de éster, carbonato, carbamato y fosfonato
US9827326B2 (en)	2010-12-23	2017-11-28	Nektar Therapeutics	Polymer-sunitinib conjugates
JP6009457B2 (ja)	2010-12-23	2016-10-19	ネクターセラピューティクス	ポリマー−デスエチルスニチニブコンジュゲート
ES2972387T3 (es)	2011-03-18	2024-06-12	Alkermes Pharma Ireland Ltd	Composiciones farmacéuticas que comprenden ésteres de sorbitán
JP6333802B2 (ja)	2012-03-19	2018-05-30	アルカームスファーマアイルランドリミテッド	ベンジルアルコールを含む医薬組成物
EP2827867B1 (de)	2012-03-19	2019-11-06	Alkermes Pharma Ireland Limited	Pharmazeutische zusammensetzungen mit glycerinestern
JP6471089B2 (ja)	2012-03-19	2019-02-13	アルカームスファーマアイルランドリミテッド	脂肪酸エステルを含む医薬組成物
EP2897592B1 (de)	2012-09-19	2020-02-19	Alkermes Pharma Ireland Limited	Pharmazeutische zusammensetzungen mit verbesserter lagerstabilität
CN110368360A (zh)	2014-03-20	2019-10-25	奥克梅斯制药爱尔兰有限公司	具有增加的注射速度的阿立哌唑制剂
CN104610231B (zh) *	2015-01-28	2016-08-17	广州葳澜生物科技有限公司	一种舒尼替尼前药
CN112423754A (zh)	2018-03-05	2021-02-26	奥克梅斯制药爱尔兰有限公司	阿立哌唑的给药策略
EP3771711A1 (de)	2019-07-29	2021-02-03	Bayer Animal Health GmbH	Pyrazolderivate für die kontrolle von arthropoden
CN114213396B (zh) *	2022-01-27	2023-03-24	深圳市乐土生物医药有限公司	一种吲哚-2-酮类化合物及其制备方法与用途

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NL230368A (de)	1957-08-19
NL45080C (de)	1935-08-22
DE683735C (de)	1936-05-12	1939-11-14	Paul Hadamovsky	Verfahren zur Kuehlung, Verfluessigung und Speicherung von Chlor und anderen aggressi Gasen
DE878539C (de)	1939-08-17	1953-06-05	Hoechst Ag	Verfahren zur Herstellung von Methinfarbstoffen
BE553661A (de)	1955-12-23
NL96047C (de)	1956-06-08
FR1398224A (fr)	1964-05-06	1965-05-07	Ici Ltd	Procédé de teinture de matières textiles de polyacrylonitrile
FR1599772A (de)	1968-09-17	1970-07-20
DE2159362A1 (de)	1971-11-30	1973-06-14	Bayer Ag	Nitrofuranderivate, verfahren zu ihrer herstellung sowie ihre verwendung als arzneimittel
DE2159360A1 (de)	1971-11-30	1973-06-14	Bayer Ag	Nitrofuranderivate, verfahren zu ihrer herstellung sowie ihre verwendung als arzneimittel
DE2159361A1 (de)	1971-11-30	1973-06-14	Bayer Ag	Nitrofuranderivate, verfahren zu ihrer herstellung sowie ihre verwendung als arzneimittel
DE2159363A1 (de)	1971-11-30	1973-06-14	Bayer Ag	Antimikrobielle mittel
GB1384599A (en)	1972-05-04	1975-02-19	Colgate Palmolive Co	Coloured detergent compositions
US4420639C1 (en)	1973-09-11	2001-08-21	Beecham Group Ltd	Aromatic compounds
US4002749A (en)	1975-08-12	1977-01-11	E. R. Squibb & Sons, Inc.	Substituted indolinones
US4053613A (en)	1975-09-17	1977-10-11	E. R. Squibb & Sons, Inc.	1,3,thiazolinyl and 1,3 thiazinyl substituted indolinones
US5389613A (en)	1979-09-21	1995-02-14	Roussel Uclaf	Method of treating prostate adenocarcinoma, prostate benign hypertrophia and endometriosis
FR2465486A1 (fr)	1979-09-21	1981-03-27	Roussel Uclaf	Nouvelle application utilisant la lh-rh ou des agonistes
EP0100172B1 (de)	1982-07-23	1987-08-12	Imperial Chemical Industries Plc	Amide-Derivate
DE3310891A1 (de)	1983-03-25	1984-09-27	Boehringer Mannheim Gmbh, 6800 Mannheim	Neue indolinon-(2)-derivate, verfahren zu ihrer herstellung, diese verbindungen enthaltende arzneimittel und zwischenprodukte
DE3426419A1 (de)	1984-07-18	1986-01-23	Boehringer Mannheim Gmbh, 6800 Mannheim	Neue oxindol-derivate, verfahren zu ihrer herstellung, diese verbindungen enthaltende arzneimittel und zwischenprodukte
JPS6229570A (ja)	1985-07-29	1987-02-07	Kanegafuchi Chem Ind Co Ltd	３，５−ジイソプロピルベンジリデン複素環式化合物
JPS6239564A (ja)	1985-08-13	1987-02-20	Kanegafuchi Chem Ind Co Ltd	α−ベンジリデン−γ−ブチロラクトンまたはγ−ブチロラクタム誘導体
WO1993012786A1 (en)	1986-07-10	1993-07-08	Howard Harry R Jr	Indolinone derivatives
JPS63141955A (ja)	1986-12-03	1988-06-14	Kanegafuchi Chem Ind Co Ltd	トリベンジルアミン誘導体
GB8816944D0 (en)	1988-07-15	1988-08-17	Sobio Lab	Compounds
GB9004483D0 (en)	1990-02-28	1990-04-25	Erba Carlo Spa	New aryl-and heteroarylethenylene derivatives and process for their preparation
CA2012634A1 (en)	1990-03-20	1991-09-20	Hassan Salari	Tyrphostins for treatment of allergic, inflammatory and cardiovascular diseases
US5196446A (en)	1990-04-16	1993-03-23	Yissum Research Development Company Of The Hebrew University Of Jerusalem	Certain indole compounds which inhibit EGF receptor tyrosine kinase
US5302606A (en)	1990-04-16	1994-04-12	Rhone-Poulenc Rorer Pharmaceuticals Inc.	Styryl-substituted pyridyl compounds which inhibit EGF receptor tyrosine kinase
WO1992007830A2 (en)	1990-10-29	1992-05-14	Pfizer Inc.	Oxindole peptide antagonists
DK0584222T3 (da)	1991-05-10	1998-02-23	Rhone Poulenc Rorer Int	Bis-mono- og bicycliske aryl- og heteroarylforbindelser, som inhiberer EGF- og/eller PDGF-receptor-tyrosinkinase
GB9115160D0 (en)	1991-07-12	1991-08-28	Erba Carlo Spa	Methylen-oxindole derivatives and process for their preparation
US5124347A (en)	1991-07-31	1992-06-23	Warner-Lambert Co.	3-5-ditertiarybutylphenyl-4-hydroxymethylidene derivatives of 1,3-dihydro-2H-indole-2-ones as antiinflammatory agents
JPH0558894A (ja)	1991-08-27	1993-03-09	Kanegafuchi Chem Ind Co Ltd	抗腫瘍剤
US5389661A (en)	1991-12-05	1995-02-14	Warner-Lambert Company	Imidazole and 1,2,4-triazole derivatives with angiotensin II antagonist properties
US5322950A (en)	1991-12-05	1994-06-21	Warner-Lambert Company	Imidazole with angiotensin II antagonist properties
US5994362A (en)	1992-03-11	1999-11-30	Merck & Co., Inc.	Method of treatment for prostatic cancer
FR2689397A1 (fr)	1992-04-01	1993-10-08	Adir	Utilisation des dérivés de la 3-(3,5-Ditert-Butyl-4-Hydroxybenzylidenyl) Indoline-2-one pour l'obtention de médicaments.
FR2694004B1 (fr)	1992-07-21	1994-08-26	Adir	Nouvelles 3-(Hydroxybenzylidényl)-indoline-2-ones et 3-(hydroxybenzylidényl)-indoline-2-thiones, leurs procédés de préparation, et les compositions pharmaceutiques qui les contiennent.
JPH07507811A (ja)	1992-10-21	1995-08-31	ファイザー・インク．	鏡像異性のシス−３−（４，６−ジヒドロキシクロマン−３−イル−メチル）安息香酸
GB9226855D0 (en)	1992-12-23	1993-02-17	Erba Carlo Spa	Vinylene-azaindole derivatives and process for their preparation
EP0632102B1 (de)	1993-06-28	1997-04-02	Bayer Ag	Massefärben von Kunststoffen
GB9313638D0 (en)	1993-07-01	1993-08-18	Erba Carlo Spa	Arylidene and heteroarylidene oxindole derivatives and process for their preparation
GB9326136D0 (en)	1993-12-22	1994-02-23	Erba Carlo Spa	Biologically active 3-substituted oxindole derivatives useful as anti-angiogenic agents
EP0748220A4 (de)	1994-01-21	1997-09-10	Sepracor Inc	Verfahren und zusammensetzungen zur behandlung von androgen-abhängigen krankheiten unter verwenddung von optisch reinem r-(-)casodex
GB9412719D0 (en)	1994-06-24	1994-08-17	Erba Carlo Spa	Substituted azaindolylidene compounds and process for their preparation
GB9423997D0 (en)	1994-11-28	1995-01-11	Erba Carlo Spa	Substituted 3-arylidene-7-azaoxindole compounds and process for their preparation
GB9501567D0 (en)	1995-01-26	1995-03-15	Pharmacia Spa	Hydrosoluble 3-arylidene-2-oxindole derivatives as tyrosine kinase inhibitors
GB9507298D0 (en)	1995-04-07	1995-05-31	Pharmacia Spa	Substituted indolylmethylene-oxindale analogues as tyrosine kinase inhibitors
US5880141A (en)	1995-06-07	1999-03-09	Sugen, Inc.	Benzylidene-Z-indoline compounds for the treatment of disease
US5777134A (en)	1995-10-26	1998-07-07	Merck & Co., Inc.	4-oxa and 4-thia steriods
CA2214759C (en)	1996-01-17	2004-05-18	Taiho Pharmaceutical Co., Ltd.	Intimal hypertrophy inhibitors
EP0788890A1 (de)	1996-02-06	1997-08-13	Agfa-Gevaert N.V.	Farbstoffe und Farbstoffdonorelemente zur thermischen Farbstoffübertragungsaufzeichnung
WO1998007695A1 (en)	1996-08-23	1998-02-26	Sugen, Inc.	Indolinone combinatorial libraries and related products and methods for the treatment of disease
WO1998024432A2 (en)	1996-12-05	1998-06-11	Sugen, Inc.	Use of indolinone compounds as modulators of protein kinases
WO1998038984A2 (en)	1997-03-05	1998-09-11	Sugen, Inc.	Formulations for hydrophobic pharmaceutical agents
EP0984930B1 (de)	1997-05-07	2005-04-06	Sugen, Inc.	2-indolinonderivate als modulatoren der proteinkinase-ativität
AU7723198A (en)	1997-06-04	1998-12-21	University Of Tennessee Research Corporation, The	Non-steroidal radiolabeled agonist/antagonist compounds and their use in prostate cancer imaging
GB9716557D0 (en)	1997-08-06	1997-10-08	Glaxo Group Ltd	Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity
US6133305A (en)	1997-09-26	2000-10-17	Sugen, Inc.	3-(substituted)-2-indolinones compounds and use thereof as inhibitors of protein kinase activity
DE19816624A1 (de)	1998-04-15	1999-10-21	Boehringer Ingelheim Pharma	Neue substituierte Indolinone, ihre Herstellung und ihre Verwendung als Arzneimittel
WO1999061422A1 (en)	1998-05-29	1999-12-02	Sugen, Inc.	Pyrrole substituted 2-indolinone protein kinase inhibitors
DE19826940A1 (de)	1998-06-17	1999-12-23	Bayer Ag	Substituierte N-Aryl-O-alkyl-carbamate
JP2002522452A (ja)	1998-08-04	2002-07-23	スージェン・インコーポレーテッド	蛋白質キナーゼの調節剤３−メチリデニル−２−インドリノン
PT1157019E (pt)	1998-12-17	2003-06-30	Hoffmann La Roche	4-alcenil (e alcinil) oxindolos como inibidores dequinases dependentes de ciclina em particular cdk2
EP1149092B1 (de)	1998-12-17	2003-10-29	F. Hoffmann-La Roche Ag	4- und 5-alkynyloxindole sowie 4- und 5-alkenyloxindole
CA2354591A1 (en)	1998-12-17	2000-06-22	F. Hoffmann-La Roche Ag	4-aryloxindoles as inhibitors of jnk protein kinases
BR9916735A (pt)	1998-12-31	2001-09-25	Sugen Inc	Compostos de 3-heteroarilidenil-2-indolinona para a modulação da atividade das cinases protéicas e para uso na quimioterapia do cancêr
AU3770000A (en)	1999-03-24	2000-10-09	Sugen, Inc.	Indolinone compounds as kinase inhibitors
CZ303705B6 (cs)	2000-02-15	2013-03-27	Sugen, Inc.	Pyrrolem substituovaná 2-indolinonová sloucenina pro pouzití jako inhibitor proteinkináz a farmaceutická kompozice s jejím obsahem
MY128450A (en) *	2000-05-24	2007-02-28	Upjohn Co	1-(pyrrolidin-1-ylmethyl)-3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives
DK1294929T3 (da) *	2000-06-07	2005-12-12	Ortho Mcneil Pharm Inc	Fremgangsmåde til påvisning af VEGF-kinasedomænemodulatorer

2001
- 2001-05-23 MY MYPI20012435A patent/MY128450A/en unknown
- 2001-05-23 TW TW090112409A patent/TWI270545B/zh not_active IP Right Cessation
- 2001-05-23 MY MYPI20012452A patent/MY128449A/en unknown
- 2001-05-24 EP EP01939357A patent/EP1301507B1/de not_active Expired - Lifetime
- 2001-05-24 AT AT01937687T patent/ATE312093T1/de not_active IP Right Cessation
- 2001-05-24 WO PCT/US2001/016756 patent/WO2001090104A2/en not_active Ceased
- 2001-05-24 EP EP01939349A patent/EP1283835A2/de not_active Ceased
- 2001-05-24 AU AU2001264877A patent/AU2001264877A1/en not_active Abandoned
- 2001-05-24 US US09/863,804 patent/US6710067B2/en not_active Expired - Fee Related
- 2001-05-24 DE DE60121595T patent/DE60121595T2/de not_active Expired - Fee Related
- 2001-05-24 EP EP01937687A patent/EP1294711B8/de not_active Expired - Lifetime
- 2001-05-24 ES ES01939357T patent/ES2269416T3/es not_active Expired - Lifetime
- 2001-05-24 ES ES01937687T patent/ES2253385T3/es not_active Expired - Lifetime
- 2001-05-24 JP JP2001586291A patent/JP2003534342A/ja active Pending
- 2001-05-24 DE DE60116487T patent/DE60116487T2/de not_active Expired - Fee Related
- 2001-05-24 JP JP2001586257A patent/JP2003534323A/ja not_active Withdrawn
- 2001-05-24 US US09/863,905 patent/US6451838B1/en not_active Expired - Fee Related
- 2001-05-24 AT AT01939357T patent/ATE333453T1/de not_active IP Right Cessation
- 2001-05-24 AR ARP010102488A patent/AR042383A1/es unknown
- 2001-05-24 WO PCT/US2001/016741 patent/WO2001090103A2/en not_active Ceased
- 2001-05-24 WO PCT/US2001/016757 patent/WO2001090068A2/en not_active Ceased
- 2001-05-24 US US09/863,819 patent/US6482848B2/en not_active Expired - Fee Related
- 2001-05-24 AU AU2001263399A patent/AU2001263399A1/en not_active Abandoned
- 2001-05-24 AR ARP010102490A patent/AR033977A1/es unknown
- 2001-05-24 AU AU2001264885A patent/AU2001264885A1/en not_active Abandoned
- 2001-05-24 JP JP2001586290A patent/JP2003534341A/ja not_active Withdrawn
- 2001-05-24 CA CA002409367A patent/CA2409367A1/en not_active Abandoned
- 2001-05-24 AR ARP010102489A patent/AR041775A1/es unknown
- 2001-05-24 CA CA002408709A patent/CA2408709A1/en not_active Abandoned
- 2001-05-24 CA CA002409430A patent/CA2409430A1/en not_active Abandoned
- 2001-05-24 HK HK03106800.4A patent/HK1054552B/en not_active IP Right Cessation
2002
- 2002-09-16 US US10/243,663 patent/US20030045565A1/en not_active Abandoned
- 2002-09-16 US US10/243,942 patent/US6716870B2/en not_active Expired - Fee Related
2003
- 2003-05-05 US US10/429,895 patent/US7008943B2/en not_active Expired - Fee Related
- 2003-12-24 US US10/743,909 patent/US7053113B2/en not_active Expired - Fee Related
2004
- 2004-02-10 US US10/774,415 patent/US7112603B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
US20020037878A1 (en)	2002-03-28
CA2409367A1 (en)	2001-11-29
HK1054552B (en)	2006-12-08
WO2001090104A2 (en)	2001-11-29
JP2003534342A (ja)	2003-11-18
WO2001090068A3 (en)	2002-06-06
US20040127544A1 (en)	2004-07-01
US6482848B2 (en)	2002-11-19
AR041775A1 (es)	2005-06-01
MY128450A (en)	2007-02-28
US7008943B2 (en)	2006-03-07
EP1283835A2 (de)	2003-02-19
US7112603B2 (en)	2006-09-26
US6710067B2 (en)	2004-03-23
EP1301507A2 (de)	2003-04-16
US20020032204A1 (en)	2002-03-14
AU2001264885A1 (en)	2001-12-03
ATE312093T1 (de)	2005-12-15
WO2001090068A2 (en)	2001-11-29
US20050107340A1 (en)	2005-05-19
EP1294711B1 (de)	2005-12-07
US7053113B2 (en)	2006-05-30
US20030045565A1 (en)	2003-03-06
EP1294711B8 (de)	2006-03-08
US20030083363A1 (en)	2003-05-01
ES2253385T3 (es)	2006-06-01
ES2269416T3 (es)	2007-04-01
CA2409430A1 (en)	2001-11-29
AR033977A1 (es)	2004-01-21
WO2001090103A2 (en)	2001-11-29
HK1054552A1 (en)	2003-12-05
EP1301507B1 (de)	2006-07-19
DE60116487D1 (de)	2006-03-30
HK1054741A1 (en)	2003-12-12
JP2003534341A (ja)	2003-11-18
AU2001263399A1 (en)	2001-12-03
TWI270545B (en)	2007-01-11
EP1294711A2 (de)	2003-03-26
US20040127542A1 (en)	2004-07-01
US20020035140A1 (en)	2002-03-21
CA2408709A1 (en)	2001-11-29
MY128449A (en)	2007-02-28
DE60121595T2 (de)	2007-07-05
US6451838B1 (en)	2002-09-17
WO2001090104A3 (en)	2002-06-13
WO2001090103A3 (en)	2002-07-18
DE60121595D1 (de)	2006-08-31
WO2001090103A9 (en)	2002-03-07
DE60116487T2 (de)	2006-08-17
AR042383A1 (es)	2005-06-22
US6716870B2 (en)	2004-04-06
AU2001264877A1 (en)	2001-12-03
JP2003534323A (ja)	2003-11-18

Legal Events

Date	Code	Title	Description
2007-01-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
DE60121595D1 (de)	2006-08-31	Mannich base prodrugs von 3-(pyrrol-2-ylmethylidene)-2-indolinon derivate und deren verwendung als protein kinase inhibitoren
ATE419849T1 (de)	2009-01-15	Diaminotriazole derivate und deren verwendung als protein kinase inhibitoren
DE60030574D1 (de)	2006-10-19	Fünfgliedrige derivate von heterozyklen und ihre verwendung als monoaminoxidase-inhibitoren
DE602004021037D1 (de)	2009-06-18	Phosphororganische indazolderivate und deren verwendung als proteinkinaseinhibitoren
ATE394102T1 (de)	2008-05-15	Substituierte chinazolin-derivate und deren verwendung als aurora-2-kinase inhibitoren
ATE299881T1 (de)	2005-08-15	4-substituierte 7-aza-indolin-2-one und ihre anwendung als protein kinase inhibitoren
DE60113719D1 (de)	2006-02-09	Chinuclidincarbamat derivate und deren verwendung als m3 antagonisten
DE69434955D1 (de)	2007-05-31	Aryliden und Heteroaryliden-oxindolderivate als Tyrosin Kinase Inhibitoren
ATE253576T1 (de)	2003-11-15	8-chinolinxanthin and 8-isochinolinxanthin derivate als pde 5 inhibitoren
CY1105618T1 (el)	2010-12-22	Δικυκλικες ετεροαρωματικες ενωσεις ως αναστολεις της κινασης τυροσινης πρωτεϊνης
ATE514676T1 (de)	2011-07-15	Ionisierbare indolinon derivate und deren verwendung als ptk liganden
ATE315553T1 (de)	2006-02-15	4-aminothiazol derivate, deren herstellung und deren verwendung als inhibitoren cyclin- abhängiger kinasen
ATE316527T1 (de)	2006-02-15	Substituierte indolinone als tyrosinkinase inhibitoren
ATE427947T1 (de)	2009-04-15	Heterocyclisch substituierte indolinone und deren verwendung als rezeptor-tyrosinkinasen inhibitoren
DE60118975D1 (de)	2006-05-24	Tetrahydropyridinderivate, deren herstellung und deren verwendung als inhibitoren der zellproliferation
CY2013005I2 (el)	2015-11-04	Κυκλικοι αναστολεις κινασης τυροσινης πρωτεϊνων
CY1108032T1 (el)	2011-04-06	Πυρρολο υποκατεστημενης 2-ινδολινονης αναστολεις κινασης πρωτεϊνης
DE60208661D1 (de)	2006-04-06	Diaminothiazole und ihre verwendung als cyclinabhängige kinase inhibitoren
ATE268761T1 (de)	2004-06-15	Substituierte quinazolin-derivate und ihre verwendung als tyrosin-kinase inhibitoren
ATE282593T1 (de)	2004-12-15	Indolin-2-on derivate und deren verwendung als liganden der ocytocin rezeptoren
CY1106165T1 (el)	2011-06-08	Παραγωγα ινδολινονης για την τροποποιηση της c-kit πρωτεϊνικης τυροσινικης κινασης
DE60013555D1 (de)	2004-10-14	Verwendung von 4-h-1-benzopyran-4-on-derivaten als inhibitoren der proliferation von glatten muskelzellen
ZA200306335B (en)	2005-01-26	3-(4-amidopyrrol-2-ylmethlidene)-2-indolinone derivatives as protein kinase inhibitors
DE59913617D1 (de)	2006-08-03	Indolderivate und deren Verwendung als Inhibitoren der Phosphodiesterase 4.
CH1175401H1 (de)	2007-02-15	Piperazin Derivate verwendbar als CCR5 Antagonisten